Skip to main content
SpringerLink
Log in

5-HT3 receptor antagonists and migraine therapy

  • Migraine Therapy And 5-HT Receptor Activity
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Summary

Neuronal 5-hydroxytryptamine3 (5-HT3) receptors mediate the excitatory effects of 5-HT. They are located in pain- and nausea-modulating areas in the central nervous system and on C-fibre primary afferents in the peripheral nervous system. Consequently, these receptors mediate the painful and emetic effects of 5-HT. Selective and potent 5-HT3 receptor antagonists have been shown to block inflammatory and 5-HT induced and potentiated “vascular pain”. Based on the hypothesis that 5-HT3 receptor antagonists may block neurogenic dural inflammation in the distribution area of the trigeminal nerve and, thus, could potentially prevent migraine (pain), four highly selective and potent 5-HT3 receptor antagonists have been tested in both the acute and prophylactic treatment of migraine. Unfortunately, except for a clear anti-emetic effect, none of these drugs has shown unequivocal efficacy in the treatment of migraine. This may be partly due to the complex (bell-shaped) dose-response relationship of these compounds, making exact titration of the correct dose difficult. Moreover, most 5-HT3 receptor antagonists have proved to be toxic in man on chronic administration thereby preventing further trials in migraine with adjusted doses. Short-term treatment for cytotoxic drug-induced emesis so far appears to be the only proven indication for 5-HT3 receptor antagonists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anthony M (1986) The biochemistry of migraine. In: Vinken PJ, Bruyn GW, Rose FC (eds) Handbook of clinical neurology, Vol 4 (48): Headache, Elsevier, Amsterdam, pp 85–105

    Google Scholar 

  2. Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposal for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–575

    Google Scholar 

  3. Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB (1988) Pharmacological properties of GR 38032F, a novel antagonist at 5-HT3 receptors. J Pharm Pharmacol 94:397–412.

    Google Scholar 

  4. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL (1990) Efficacy of Ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810–816

    Google Scholar 

  5. Dahlöf C, Winter P, Ludlow S (1989) Oral GR43175, a 5HT1-like agonist, for treatment of the acute migraine attack: an international study preliminary results. Cephalalgia 9 (suppl 10):350–351

    Google Scholar 

  6. Edvinsson L, Degueurce A, Duverger D, MacKenzie ET, Scatton B (1983) Central serotonergic nerves project to the pial vessels of the brain. Nature 306:55–57

    Google Scholar 

  7. Ferrari MD, Bayliss EM, Ludlow S, Pilgrim AJ (1989) Subcutaneous GR43175 in the treatment of acute migraine: an international study. Cephalalgia 9 (suppl 10):348–349

    Google Scholar 

  8. Ferrari MD, Odink J, Tapparelli C, Van Kempen GMJ, Pennings EJM, Bruyn GW (1989) Serotonin metabolism in migraine. Neurology 39:1239–1242

    Google Scholar 

  9. Ferrari MD, Wilkinson M, Hirt D, Lataste X (1990) Efficacy of ICS 205930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. Pain (in press)

  10. Fitzgerald M (1989) Arthritis and the nervous system. Trends Pharmacol Sci 12:86–88

    Google Scholar 

  11. Fozard JR (1982) Basic mechanisms of antimigraine drugs. In: Critchley M, Friedman A, Gorini S, Sicuteri F (eds) Advances in neurology, Vol 33. Raven Press, New York, pp 295–307

    Google Scholar 

  12. Fozard JR (1984) MDL-72222, a potent and highly selective antagonist at neuronal 5-hydroxytryptamine M-receptors. Naunyn Schmiedebergs Arch Pharmacol 326:36–44

    Google Scholar 

  13. Fozard JR (1984) Neuronal 5-HT receptors in the periphery. Neuropharmacology 23:1473–1476

    Google Scholar 

  14. Fozard JR (1990) Agonists and antagonists of 5-HT3 receptors. In: Saxena PR, Wallis DJ, Wouters W, Bevan P (eds) Cardiovascular pharmacology of 5-hydroxytryptamine. Kluwer. Dordrecht, pp 101–115

    Google Scholar 

  15. Fozard JR (1990) 5-HT3 receptors. In: Paoletti R, Vanhoutte PM, Brunello N, Maggi FM (eds) Serotonin: from cell biology to pharmacology and therapeutics. Kluwer, Dordrecht, pp 331–338

    Google Scholar 

  16. Fozard JR, Mobarok Ali ATM (1978) Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 49:109–112

    Google Scholar 

  17. Fozard JR, Mobarok Ali ATM, Newgrosh G (1979) Blockade of serotonin receptors on autonomic neurones by (-)-cocaine and some related compounds. Eur J Pharmacol 59:195–210

    Google Scholar 

  18. Gaddum JH, Picarelli ZP (1957) Two kinds of tryptamine receptor. Br J Pharmacol Chemother 12:323–328

    Google Scholar 

  19. Giordano J, Dyche J (1989) Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse. Neuropharmacology 28:423–427

    Google Scholar 

  20. Giordano J, Rogers LV (1989) Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. Eur J Pharmacol 170:83–86

    Google Scholar 

  21. Glaum SR, Anderson EG (1988) Identification of 5-HT3 binding sites in rat spinal cord synaptosomal membranes. Eur J Pharmacol 156:287–290

    Google Scholar 

  22. Gralla RJ, Kris MG, Clarke RA, Tyson LB (1988) Randomassignment anti-emetic trial of different dosage schedules of the serotonin antagonist GR-C507/75 (38032F) in patients receiving high dose cisplatin. Proc ASCO 7:296

    Google Scholar 

  23. Griffith SG, Burnstock G (1983) Immunohistochemical demonstration of serotonin in nerves supplying human cerebral and mesenteric vessels. Lancet I:561–562

    Google Scholar 

  24. Hughes JB (1977) Metoclopramide in migraine. Med J Aust II:580

    Google Scholar 

  25. Humphrey PPA (1991) 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 238 (suppl 1):S38-S44

    Google Scholar 

  26. Kilpatrick GJ, Jones BJ, Tyrers MB (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330:746–748

    Google Scholar 

  27. Kilpatrick GJ, Jones BJ, Tyrers MB (1990) Brain 5-HT3 receptors. In: Paoletti R, Vanhoutte PM, Brunello N, Maggi FM (eds) Serotonin: from cell biology to pharmacology and therapeutics. Kluwer, Dordrecht, pp 339–345

    Google Scholar 

  28. King FD, Sanger GJ (1989) 5-HT3 receptor antagonists. Drugs Future 14:875–889

    Google Scholar 

  29. Lance JW, Lambert GA, Goadsby PJ, Zagami AS (1989) 5-Hydroxytryptamine and its putative aetiological involvement in migraine. Cephalalgia 9 (suppl 9):7–13

    Google Scholar 

  30. Lataste X, Ferrari MD, Hirt D, Notter M, Wilkinson M (1989) Efficacy and tolerability of ICS 205930, a 5-HT3 receptor antagonist in migraine prophylaxis. Cephalalgia 9 (suppl 10):346–347

    Google Scholar 

  31. Loisy C, Beorchia S, Centonze V, Fozard JR, Schlecter PJ, Tell GP (1985) Effects on migraine headache of MDL 72222, an antagonist at neuronal 5-HT receptors. Double-blind placebo controlled study. Cephalalgia 5:79–82

    Google Scholar 

  32. Moskowitz MA, Buzzi MG (1991) Neuroeffector functions of sensory fibres: implications for headache mechanisms and drug actions. J Neurol 238 (suppl 1):S18-S22

    Google Scholar 

  33. Moskowitz MA, Henrikson BM, Markowitz S, Saito K (1988) Intra- and extracraniovascular nociceptive mechanisms and the pathogenesis of headpain. In: Olesen J, Edvinsson L (eds) Basic mechanism of headache. Elsevier, Amsterdam, pp 429–437

    Google Scholar 

  34. Moss HE, Sanger GJ (1987) Antagonism by BRL 43694 of the pseudoaffective reflex induced by duodenal distension. Br J Pharmacol 92:531P

    Google Scholar 

  35. Patten JP (1991) Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. J Neurol 238 (suppl 1):S62-S65

    Google Scholar 

  36. Pratt GD, Bowery NG, Kilpatrick GJ, Leslie RA, Barnes NM, Naylor RJ, Jones BJ, Nelson DR, Palacios JM, Slater P, Reynolds JM (1990) Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. Trends Pharmacol Sci 11:135–137

    Google Scholar 

  37. Richardson BP, Engel G (1986) The pharmacology and function of 5-HT3 receptors. Trends Neurol Sci 9:424–428

    Google Scholar 

  38. Richardson BP, Engel G, Donatsch P, Stadler PA (1985) Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316:126–131

    Google Scholar 

  39. Sanger GJ (1987) Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924. Br J Pharmacol 91:77–87

    Google Scholar 

  40. Saxena PR, Ferrari MD (1989) 5-Hydroxytryptamine1-like receptor agonists and migraine: possible impact on the pathophysiology of migraine. Trends Pharmacol Sci 10:200–204

    Google Scholar 

  41. Scatton B, Duverger D, L'Heureux R, Serrano A, Fage D, Nowicki J-P, MacKenzie ET (1985) Neurochemical studies on the existence, origin and characteristics of the serotonergic innervation of small pial vessels. Brain Res 345:219–229

    Google Scholar 

  42. Sicuteri F, Fanciullacci M, Franchi G, Del Bianco PL (1965) Serotonin-bradykinin potentiation on the pain receptors in man. Life Sci 4:309–316

    Google Scholar 

  43. Smith WW, Sancilio LF, Owera-Atepo JB, Naylor RJ, Lambert L (1988) Zacopride, a potent 5-HT3 antagonist. J Pharm Pharmacol 40:301–302

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital Leiden, P. O. Box 9600, 2300 RC, Leiden, The Netherlands

    M. D. Ferrari

Authors
  1. M. D. Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferrari, M.D. 5-HT3 receptor antagonists and migraine therapy. J Neurol 238 (Suppl 1), S53–S56 (1991). https://doi.org/10.1007/BF01642907

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01642907

Key words

Search

Navigation